Comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 vs 46 Xx Gonadal Dysgenesis C0685837
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Fetoplacental Androgens Excess and 46 XX Gonadal Dysgenesis for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
A condition where the placenta and fetus together produce excess androgens, affecting an XX embryo's development. It is present at birth. Multidisciplinary care helps manage physical and hormonal aspects.
46 Xx Gonadal Dysgenesis C0685837
A condition affecting ovarian development in individuals with two X chromosomes. May impact puberty and fertility. Treatment typically includes hormone replacement and supportive care.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Variable
46 Xx Gonadal Dysgenesis C0685837
12-16
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
severe
46 Xx Gonadal Dysgenesis C0685837
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Chronic
46 Xx Gonadal Dysgenesis C0685837
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
No
46 Xx Gonadal Dysgenesis C0685837
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
reproductive
46 Xx Gonadal Dysgenesis C0685837
reproductive
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
endocrine
46 Xx Gonadal Dysgenesis C0685837
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-fetoplacental-androgens-excess-C5679876 and 46-xx-gonadal-dysgenesis-C0685837 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 46 Xx Gonadal Dysgenesis C0685837 | Discriminating power |
|---|---|---|---|
| Genital appearance at birth | Atypical or virilized external genitalia may be present from prenatal androgen exposure. | External genitalia are often typical female at birth; this is not definitive. | Moderate |
| Pubertal development | Puberty may be altered, but the supplied data do not define a single pattern. | Absent, delayed, or incomplete puberty and fertility concerns may appear around ages 12–16. | Moderate |
| Primary mechanism | Excess androgen effect during fetal development, categorized as endocrine. | Impaired ovarian or gonadal development, categorized as genetic. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 when
Atypical genitalia recognized at birth in a 46,XX infant
Prenatal androgen exposure fits the supplied onset and endocrine mechanism better than pubertal ovarian failure.
Moderate
History suggesting excess androgen during pregnancy
A fetoplacental source is central to the left concept, but the history alone is not diagnostic.
Moderate
Severe congenital reproductive difference needing early multidisciplinary care
The source labels the left condition severe and present at birth.
Low
Choose 46 Xx Gonadal Dysgenesis C0685837 when
Typical childhood appearance with absent or incomplete puberty
The supplied onset is about ages 12–16 and centers on ovarian development.
Moderate
Primary amenorrhea or infertility evaluation in a 46,XX person
Puberty and fertility are the stated clinical concerns; other causes still require exclusion.
Moderate
Imaging or histology suggests underdeveloped gonads
Gonadal dysgenesis concerns gonadal development rather than excess fetal androgen exposure.
Moderate
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 46 Xx Gonadal Dysgenesis C0685837 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XX by definition; other chromosomal findings would change the classification. | 46,XX by definition; Y-chromosome material should be excluded when clinically relevant. | A shared karyotype does not distinguish the conditions. |
| Hormone assessment | Androgen-related abnormalities may be sought; no cutoff is established here. | Pubertal hormone pattern may suggest impaired ovarian function; no cutoff is established here. | Results are clues only and require clinician and laboratory interpretation. |
| Pelvic imaging or gonadal assessment | Anatomy may reflect androgen exposure; findings are variable and not specified here. | Underdeveloped or streak gonads may be found, but imaging alone is not diagnostic. | Correlate with genetics, hormones, and clinical course. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
- Outcome
- Chronic condition with potentially severe physical and hormonal effects; individual outcome is not established.
- Factors
- Degree of prenatal androgen exposure, anatomy, hormone findings, and access to multidisciplinary care.
46 Xx Gonadal Dysgenesis C0685837
- Outcome
- Chronic moderate condition that may affect puberty and fertility; many outcomes depend on the exact cause.
- Factors
- Gonadal function, timing of recognition, hormone treatment, and psychosocial support.
Time frame: From birth or puberty across adolescence and adulthood; no universal timeline is established.
Precise diagnosis, associated conditions, treatment response, and patient preferences.
Complications comparison
| Complication | Presentation |
|---|---|
| Puberty and fertility | Hormonal and reproductive effects may persist; exact outcomes are not established. Puberty and fertility are commonly affected and may need hormone replacement and support. Neither outcome should be predicted from the label alone. |
| Anatomic and psychosocial impact | Congenital genital difference can require sensitive multidisciplinary care. Impact may emerge later through delayed puberty, amenorrhea, or infertility. Care should be individualized and non-stigmatizing. |
| Associated medical risk | Specific complication rates are not supplied and should not be assumed. Long-term risks depend on the exact diagnosis and are not established here. Clinicians should assess bone, endocrine, and psychosocial needs. |
Patient education highlights
- HighDiagnosis is a process
A karyotype or one abnormal finding is not a complete diagnosis. Ask how hormone, imaging, and genetic results fit together.
- HighCare team
Endocrinology, genetics, gynecology or urology, and psychosocial support may all be appropriate.
- MediumLanguage and privacy
Discuss preferred terms, confidentiality, and timing of information sharing, especially for children and adolescents.